219 related articles for article (PubMed ID: 28787745)
1. Cardiovascular effects of some antidiabetic drugs.
Med Lett Drugs Ther; 2017 Aug; 59(1527):136-138. PubMed ID: 28787745
[No Abstract] [Full Text] [Related]
2. London buses: A cardiovascular outcome trial equivalent?
Grant PJ
Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
[No Abstract] [Full Text] [Related]
3. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
4. Incretins: cardiovascular safety and rationale for use.
Kok A
Cardiovasc J Afr; 2013 Mar; 24(2):46. PubMed ID: 23750348
[No Abstract] [Full Text] [Related]
5. ORIGIN trial shows safety and efficacy of insulin glargine: no adverse cardiovascular outcomes after a 6.2-year follow up of early insulin use.
Lombard L; Distiller L; Aalbers J
Cardiovasc J Afr; 2012 Jul; 23(6):357-8. PubMed ID: 23091824
[No Abstract] [Full Text] [Related]
6. Novo Nordisk incretin and Cardiovascular Summit, Durban, June 2013.
Wagenaar P
Cardiovasc J Afr; 2013 Sep; 24(8):340. PubMed ID: 24240386
[No Abstract] [Full Text] [Related]
7. Diabetes: Time for reconciliation between cardiologists and diabetologists.
Scheen AJ
Nat Rev Cardiol; 2016 Sep; 13(9):509-10. PubMed ID: 27411401
[No Abstract] [Full Text] [Related]
8. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
Bonadonna RC; Borghi C; Consoli A; Volpe M
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
[TBL] [Abstract][Full Text] [Related]
9. Current perspectives on cardiovascular outcome trials in diabetes.
Schnell O; Rydén L; Standl E; Ceriello A;
Cardiovasc Diabetol; 2016 Oct; 15(1):139. PubMed ID: 27716274
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
[TBL] [Abstract][Full Text] [Related]
11. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment.
Gore MO; McGuire DK
Diab Vasc Dis Res; 2012 Apr; 9(2):85-8. PubMed ID: 22496441
[No Abstract] [Full Text] [Related]
12. [Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
Olšovský J
Vnitr Lek; 2016; 62(7-8):613-5. PubMed ID: 27627086
[TBL] [Abstract][Full Text] [Related]
13. Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions.
Kato ET; Das SR; McGuire DK
Trends Cardiovasc Med; 2021 Feb; 31(2):101-108. PubMed ID: 31982285
[TBL] [Abstract][Full Text] [Related]
14. Improved knowledge of antidiabetic treatment--a necessity for the modern cardiologist.
Wikström G; Malmberg K; Rydén L
Eur Heart J; 1999 Mar; 20(6):403-5. PubMed ID: 10213343
[No Abstract] [Full Text] [Related]
15. [Glitazones critically evaluated].
Schernthaner G
Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
[No Abstract] [Full Text] [Related]
16. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
Zechmann S
Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
[No Abstract] [Full Text] [Related]
17. Cardiovascular Safety Trials of Antidiabetic Therapies to Treat Type 2 Diabetes: Perhaps Asking the Wrong Question?
Psaty BM; Fleming TR
Am J Hypertens; 2019 Sep; 32(10):927-929. PubMed ID: 31175821
[No Abstract] [Full Text] [Related]
18. [Too positive comment on glitazones].
Lindberg M
Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
[No Abstract] [Full Text] [Related]
19. Implications of cardiovascular outcome trials with injectable antidiabetic agents.
Pratley RE
J Diabetes; 2018 Oct; 10(10):801-803. PubMed ID: 29971941
[No Abstract] [Full Text] [Related]
20. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
Masmiquel L
Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
